TAK vs NVO vs LLY vs AZN vs PFE

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Novo Nordisk A/S (NVO) offers the better valuation at 12. 6x trailing P/E (2. 1x forward), making it the more compelling value choice. Analysts rate Takeda Pharmaceutical Company Limited (TAK) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novo Nordisk A/S (NVO) is the cheapest at 12.

6x versus Takeda Pharmaceutical Company Limited at 77. 4x. On forward P/E, Takeda Pharmaceutical Company Limited is actually cheaper at 0. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Takeda Pharmaceutical Company Limited wins at 0. 01x versus Eli Lilly and Company's 0. 98x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +411.

1%, compared to -13. 3% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: LLY returned +1238% versus TAK's -1. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Takeda Pharmaceutical Company Limited (TAK) is the lower-risk stock at 0.

33β versus Novo Nordisk A/S's 1. 56β — meaning NVO is approximately 379% more volatile than TAK relative to the S&P 500. On balance sheet safety, AstraZeneca PLC (AZN) carries a lower debt/equity ratio of 61% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: AstraZeneca PLC grew EPS 190. 7% year-over-year, compared to -26. 2% for Takeda Pharmaceutical Company Limited. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novo Nordisk A/S (NVO) is the more profitable company, earning 33.

1% net margin versus 2. 4% for Takeda Pharmaceutical Company Limited — meaning it keeps 33. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 7. 5% for TAK. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Takeda Pharmaceutical Company Limited (TAK) is the more undervalued stock at a PEG of 0. 01x versus Eli Lilly and Company's 0. 98x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Takeda Pharmaceutical Company Limited (TAK) trades at 0. 2x forward P/E versus 28. 2x for Eli Lilly and Company — 28. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LLY: 29. 1% to $1258. 47.

All stocks in this comparison pay dividends.

Pfizer Inc. (PFE) offers the highest yield at 6. 5%, versus 0. 6% for Eli Lilly and Company (LLY).

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

71), 0. 6% yield, +1238% 10Y return). Novo Nordisk A/S (NVO) carries a higher beta of 1. 56 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1238%, NVO: +99. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TAK is a mid-cap income-oriented stock; NVO is a large-cap deep-value stock; LLY is a large-cap high-growth stock; AZN is a large-cap quality compounder stock; PFE is a mid-cap income-oriented stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.